Neurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada.
Neurology, University of Pennsylvania, Philadelphia, United States.
Sci Rep. 2024 Nov 25;14(1):29135. doi: 10.1038/s41598-024-75290-8.
Our objective was to evaluate the individual and combined prognostic attributes of baseline serum and CSF measurements of Neurofilament light chain (sNfL, cNfL) and glial fibrillary acidic protein (sGFAP, cGFAP) on long term clinical outcomes in MS. In this retrospective single center study, patients with serum and CSF stored at first MS presentation and > 15-years of follow-up were analyzed. NfL and GFAP were quantified from cryopreserved samples using a digital immunoassay and analyzed as predictors of confirmed disability worsening (CDW). Sixty patients (70% female) underwent baseline tandem CSF and serum sampling and were followed for a mean of 17.8 years (SD 2.5). 32 developed CDW. By logistic regression, while sNfL cNfL and cGFAP showed prognostic merit (AUC 0.72, 0.70, 0.62 respectively), sGFAP did not (AUC 0.5). The combination of cNfL and cGFAP improved CDW prediction compared to either measure considered in isolation (AUC 0.72). The optimal predictive cut-off for CDW (Youden's index) for cNfL was 596 pg/mL and for cGFAP was 8160 pg/mL. Kaplan-Meier analysis of the cutoff-defined 'high-high' and 'low-low' combined cNfL and cGFAP groupings improved prediction of CDW compared to either marker individually (Hazard ratio 4.5 (95% CI 2.7-18.3), Logrank P < 0.0001). Cox Proportional Hazards regression demonstrated that high baseline cNfL and cGFAP were independently prognostic of subsequent CDW after adjusting for baseline age, sex, EDSS score and subsequent treatment exposure. Each unit increase in Ln(cNfL) and Ln(cGFAP) was respectively associated with an additional hazard of 2.36 (95% CI 1.12-5.52) and 2.26 (95% CI 1.03-5.21). CSF NfL and GFAP are independently prognostic of long-term clinical worsening in MS, and may represent a complementary pairing.
我们的目的是评估基线血清和脑脊液中神经丝轻链(sNfL、cNfL)和胶质纤维酸性蛋白(sGFAP、cGFAP)的个体和联合预后属性,以预测 MS 的长期临床结局。在这项回顾性单中心研究中,分析了首次 MS 发作时储存的血清和脑脊液,并随访了>15 年。使用数字免疫测定法从冷冻保存的样本中定量测定 NfL 和 GFAP,并将其分析为确认残疾进展(CDW)的预测因子。60 名患者(70%为女性)接受了基线串联 CSF 和血清取样,并平均随访 17.8 年(SD 2.5)。32 例发生 CDW。通过逻辑回归,sNfL、cNfL 和 cGFAP 具有预后价值(AUC 分别为 0.72、0.70 和 0.62),而 sGFAP 则没有(AUC 为 0.5)。与单独考虑任何一项测量相比,cNfL 和 cGFAP 的组合可改善 CDW 的预测(AUC 为 0.72)。用于 CDW 的最佳预测截断值(Youden 指数)为 cNfL 为 596pg/mL,cGFAP 为 8160pg/mL。根据截断值定义的“高-高”和“低-低”联合 cNfL 和 cGFAP 分组的 Kaplan-Meier 分析,与单独使用任何一种标志物相比,均可改善 CDW 的预测(风险比 4.5(95%CI 2.7-18.3),Logrank P<0.0001)。Cox 比例风险回归表明,在校正基线年龄、性别、EDSS 评分和随后的治疗暴露后,高基线 cNfL 和 cGFAP 与随后的 CDW 独立相关。Ln(cNfL)和 Ln(cGFAP)每增加一个单位,分别与 2.36(95%CI 1.12-5.52)和 2.26(95%CI 1.03-5.21)的额外风险相关。CSF NfL 和 GFAP 是 MS 长期临床恶化的独立预后因素,可能是互补配对。